Escherichia coli O157:H7 Hemorrhagic Colitis

Phillip I. Tarr, Marguerite A. Neill, Dennis L. Christie, Donald E. Anderson

Research output: Contribution to journalLetterpeer-review

31 Scopus citations


To the Editor: Like Carter et al.1 in their article and Sack in his editorial2 in the December 10 issue, we too are concerned that antibiotic treatment of hemorrhagic colitis may increase the risk of hemolytic uremic syndrome. Escherichia coli O157:H7, an organism that produces Shiga-like toxins (also called verocytotoxins), is the enteric pathogen most commonly isolated from patients with hemolytic uremic syndrome.3 4 5 6 7 Current concepts of pathogenesis focus on the role of these toxins in systemic cellular injury that results in the microangiopathy and nephropathy of hemolytic uremic syndrome.8 Antibiotics could influence this pathophysiologic sequence by two mechanisms. The first,.

Original languageEnglish
Number of pages1
JournalNew England Journal of Medicine
Issue number25
StatePublished - Jun 23 1988


Dive into the research topics of 'Escherichia coli O157:H7 Hemorrhagic Colitis'. Together they form a unique fingerprint.

Cite this